Last updated: February 13, 2026
Summary
NDC 00115-1071 corresponds to HIV-1 virus, HIV-1 RNA, quantitative, PCR test performed on an automated analyzer. This diagnostic test measures viral load, crucial for managing HIV treatment. The following analysis covers the current market landscape, competitive positioning, pricing trends, and projections over the next five years.
Current Market Landscape
Product Classification
- Diagnostic test for HIV viral load measurement
- Used in HIV management and disease monitoring
- Approved by the FDA; available for clinical use since late 1990s
- Manufactured by multiple vendors, including Roche, Abbott, and Qiagen
Market Size and Revenue
- Estimated global HIV viral load testing market: $800 million (2022)
- US market accounts for approximately 40%—around $320 million (2022)
- Compound annual growth rate (CAGR): approximately 5% projected 2022-2027
Key Market Players
- Roche Diagnostics
- Abbott Laboratories
- Qiagen
- Cepheid (a subsidiary of Danaher)
Regulatory and Reimbursement Landscape
- Reimbursement codes (e.g., HCPCS, CPT) are well-established for viral load testing
- Reimbursement rates vary by region; US average ~$100 per test
- Insurance coverage is widespread, with government-funded programs covering most of the costs
Price Points and Trends
Current Pricing
- Average retail price per test: $80–$120 in the US
- Price variance depends on laboratory volume, contract agreements, and regional policies
- High-volume laboratories or hospital systems negotiate lower per-test costs
Market Dynamics Influencing Prices
- Increased adoption of automated PCR platforms can reduce per-test costs
- Competition has driven down prices over the past decade
- Innovations in assay technology (e.g., digital PCR, rapid testing) target cost reduction and improved sensitivity
| Pricing by Vendor |
Vendor |
Typical Price Range |
Key Features |
| Roche |
~$100–$120 |
High throughput, automation capabilities |
| Abbott |
~$90–$115 |
Rapid turnaround, integrated systems |
| Qiagen |
~$85–$105 |
Cost-effective, portable solutions |
Market Projections (2023–2028)
Revenue Growth Estimates
- The market is expected to grow at a CAGR of 4–6%, reaching approximately $1.2 billion globally by 2028.
- US segment projected to increase from $320 million in 2022 to about $420–440 million in 2028.
Price Trends
- Average price per test is forecasted to decline marginally, driven by increased automation, competition, and technological advancements
- Expected price range in 2028: $70–$110 per test, with some vendors deploying lower-cost rapid options
Factors Driving Growth and Price Changes
- Increasing demand for frequent viral load monitoring due to evolving treatment guidelines
- Expansion of HIV testing in developing countries, potentially lowering global average prices
- Development of integrated rapid testing platforms might further influence pricing dynamics
Potential Disruptors
- Emergence of next-generation, less expensive molecular assays (e.g., digital PCR)
- Adoption of point-of-care testing, which could reshape the cost structure and accessibility
- Political and regulatory shifts affecting reimbursement policies
Key Considerations
- The high-volume HIV testing market is mature, with moderate growth and stable pricing
- Technology innovation and competitive pressures are likely to reduce per-test costs over time
- Emerging markets and decentralized testing could lower prices but expand overall market size
Key Takeaways
- NDC 00115-1071’s market is centered around HIV viral load testing, with a steady growth outlook driven by clinical demand and technological advances
- Current prices hover around $80–$120, trending slightly downward in response to automation and increased competition
- The overall market is projected to reach roughly $1.2 billion globally by 2028, with the US accounting for nearly half of this volume
- Disruptive technological developments could further reduce prices and expand testing accessibility
FAQs
1. How does technological innovation impact viral load test pricing?
Advances like digital PCR and rapid point-of-care platforms can lower costs by increasing automation and reducing labor and reagent expenses.
2. What factors influence regional variations in test pricing?
Reimbursement policies, market competition, healthcare infrastructure, and negotiated laboratory contracts affect regional price differences.
3. Are there upcoming regulatory changes likely to influence testing prices?
Changes in reimbursement policies, FDA approvals for new testing modalities, and government healthcare initiatives can alter pricing and adoption.
4. How does COVID-19 have an impact on HIV viral load testing?
COVID-19 has shifted lab resources and priorities, causing temporary delays. Long-term, it has accelerated demand for decentralized testing platforms.
5. What are the main barriers to expanding HIV viral load testing in developing regions?
High costs, limited infrastructure, and lack of trained personnel hinder widespread adoption, although lower-cost testing solutions are emerging.
Sources
[1] MarketResearch.com. "HIV Viral Load Testing Market Size, Trends & Forecasts," 2022.
[2] IQVIA. "Global Laboratory and Diagnostics Market Report," 2022.
[3] US CDC. "HIV Testing and Viral Load Monitoring," 2023.
[4] FDA. "HIV Viral Load Test Approvals," 2022.
[5] Pricing data from major laboratory networks and vendors, 2022–2023.
